Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®
← catalyst calendarNCT05230550 · readout in 133 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
200estimated
Sites
47
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-03 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-02-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Adult Growth Hormone Deficiency
Intervention
- Drug: Somapacitan — also filed as Sogroya®
Primary outcomes
what the primary-completion date above is the date OFNumber of adverse events
measured From baseline (week 0) to end of study (up to 260 weeks)
Number of serious adverse events
measured From baseline (week 0) to end of study (up to 260 weeks)
Number of serious adverse reactions
measured From baseline (week 0) to end of study (up to 260 weeks)
Number of adverse reactions
measured From baseline (week 0) to end of study (up to 260 weeks)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed